clinical trial · NCT07229625
A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)
Suzhou Suncadia Biopharmaceuticals Co., Ltd.·phase3·recruiting·n = 604
Advanced Biliary Tract CancerSHR-8068 InjectionAdebrelimab InjectionGemcitabine Hydrochloride for InjectionCisplatin InjectionDurvalumab Injection
brief summary
This study is a randomized, open-label, multicenter phase III clinical trial, aiming to evaluate the efficacy and safety of SHR-8068 combined with adbelimab and platinum-based chemotherapy in contrast to varicumab combined with platinum-based chemotherapy in the first-line treatment of patients with advanced BTC.
started
Jan 21, 2026
primary completion
Dec 1, 2029
completion
Dec 1, 2029
last updated
Jan 28, 2026
official title
A Phase III, Randomized, Controlled, Open-Label, Multicenter Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-Line Treatment for Advanced Biliary Tract Cancer (BTC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol